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Abstract
Background: HLA-DR*04 was identified as a predictor of HIV-Associated neurocognitive disorder (HAND), low CD4 T-cell
responses to HIV, and low plasma HIV RNA levels in a U.S. cohort. We hypothesized that low CD4 T-cell activation leads to
poor immune control of HIV in the CNS, predisposing to HAND, but also provided fewer target (activated CD4 T-cells) for
HIV replication. To assess the consistency of these HLA Class II associations in a new cohort and extend analysis to HLA Class
I, HLA types, neurocognitive, and virologic status were examined in a cohort of former plasma donors in China.
Methods: 178 HIV infected individuals in Anhui China, were HLA typed and underwent neurocognitive evaluations (using
locally standardized norms), neuromedical, treatment and virologic assessments at baseline and at 12 months.
Results: HLA DR*04 was associated with a higher rate of baseline neurocognitive impairment (p=0.04), neurocognitive
decline (p=0.04), and lower levels of HIV RNA in plasma (p=0.05). HLA Class I alleles (B*27,57,58,A*03,33) that specify a CD8
T-cell response to conserved HIV sequences were neuroprotective, associated with less impairment at baseline (p=0.037), at
month 012 (p=0.013) and less neurocognitive decline (p=0.023) in the interval. Consistent with the theory that effective
CD8 T-cell responses require CD4 T-cell support, the HLA DR*04 allele reduced the neuroprotective effect of the Class I
alleles. The presence of HLA-DR*04 and the Alzheimer associated allele ApoE4 in the same individual had a synergistic
negative effect on cognition (p=0.003).
Conclusions: Despite major background differences between U.S. and Anhui China cohorts, HLA DR*04 predicted
neurocognitive impairment and lower plasma HIV RNA levels in both populations. HLA Class I alleles associated with CD8 T-
cell control of HIV were associated with protection from HAND, but protection was reduced in the presence of HLA-DR*04.
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Introduction
Differential levels of immune control of HIV and highly
variable disease course suggest that host genetics influence HIV
disease progression. Since HLA A, B, and DRB1 gene loci
specify immune cell recognition and activation, potentially
influencing both protective and pathogenic responses, HLA
genes are logical genetic candidates. HLA association studies are
complicated by the extensive diversity at the 3 main loci (A, B,
DRB1) and the requirement for large sample sizes. Despite
these obstacles, independent studies have now linked specific
HLA types with high or low risk for HIV seroconversion,
immunologic control, and disease progression [1,2,3,4,5,6,7,8].
Findings from a number of groups agree that certain HLA
A and B alleles (HLA B*27 B*57, 58, in US and Western
European cohorts) present conserved regions of HIV gag and
nef to T-cells [1,9,10,11,12]. The hypothesis is that individuals
with these alleles have effective anti-HIV CD8 T-cells that
maintain immune control of HIV because virus escape
mutations in these conserved regions result in significant loss
of replicative fitness [10,13,14]. Therefore the CD8 T-cells in
these individuals tend to remain effective and if escape mutants
are viable, they grow slowly. In either case, individuals with
such alleles tend to have a slower rate of HIV disease
progression. However, it is not yet clear whether there are
specific alleles that increase or decrease risk of HIV associated
neurocognitive disorder (HAND) or whether alleles that are
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HAND.
Mild to moderate neuropsychological impairment can be
detected in 30–40% of HIV infected cohorts, and affects an
individual’s ability to work, day to day functioning, and quality
of life [15,16,17] [18]. Antiretroviral treatment (ART), while
significantly reducing incidence of HIV encephalitis, plasma
HIV RNA, and reconstituting CD4 numbers and resistance to
opportunistic infections, has had a less dramatic impact on
chronic HAND, increasing the relative visibility of moderate
cognitive impairment in otherwise well managed cohorts [17].
As it becomes feasible to target CNS infection therapeutically,
there is increasing interest in identifying genetic phenotypes that
either predispose or protect the host from HAND. In an earlier
cohort of 191 HIV-infected, HLA typed persons in the United
States [19], HLA DR alleles that presented relatively few HIV
peptides (especially HLA DR*04) were associated with a higher
risk of HAND, but also, unexpectedly, low plasma HIV RNA
levels. In contrast, those individuals with HLA DR types with
broad peptide recognition had a lower risk of HAND, but
comparatively higher HIV RNA levels [4]. Our explanation for
the differences in HIV RNA levels was that individuals with
broad response alleles had more activated CD4 T-cells to host
HIV replication, while those with low CD4 responses (and
activation) had fewer permissive host cells and consequently less
HIV replication. The higher risk of HAND in the low CD4
response subgroup could be due to a lack of CD4 help for HIV
specific CD8 T-cells, whose role is to migrate into the CNS and
destroy HIV infected cells. Lack of CD4 support for CD8 T-
cells [20] would permit spread of HIV and associated
inflammation, leading to greater risk of neurocognitive impair-
ment.
Recent studies from other groups are relevant to our initial
report. HLA DR*04, which was linked to low (and narrow)
CD4 T-cell responses to HIV is also reportedly associated with
low CD4 T-cell responses to mitogens in Autism Spectrum
Disorder [21,22]. In the HIV field, specific HLA Class I (A and
B) alleles that encode for protective CD8 recognition have been
identified. HLA Class I alleles (B*27, B*57, B*58) that present
conserved regions (mostly gag and nef) of HIV appear to
protect against HIV disease progression and are at higher
frequencies in long term non progressor and virus controller
groups [1,10,12,23,24,25].
A robust method of testing genetic hypotheses is to re-
examine the allele associations in a new, non-overlapping
cohort. Our research group’s study in China presented an
opportunity to validate our previous findings concerning HLA
and HAND and extend our investigation in a new and
ethnically different population. Several studies in China have
reported on associations between HLA genes, HIV seroconver-
sion and progression to an AIDS diagnosis, as well as T-cell
recognition, providing important information on local allele
frequencies for updating hypotheses. Based on our previous
results and (other’s) findings for Class I alleles, we proposed to
assess whether the HLA Class II allele previously identified,
HLA DR*04, was associated with neurocognitive impairment,
decline, and low HIV RNA levels. We also asked whether Class
I alleles that present conserved peptides of HIV and are
associated with slow disease progression (in the US and China)
are also associated with protection from neurocognitive impair-
ment. In addition, because a previous study of genetic variants
associated with neurocognitive impairment in this cohort
identified an association with ApoE4, the role of ApoE4 in
mediating the HLA effects was also examined [26].
Methods
Participants
The grant that supported this study: ‘‘The Neurobehavioral
Effects of HIV infection and Host Genetics in China’’ was
approved by the University of California San Diego Institutional
Review Board (IRB), and the IRBs of the National Center for
AIDS/STD Control and Prevention, Beijing, China and Beijing
Mental Health Institute, Peking University. Data collection,
confidentiality, and genetic analyses were as proposed in the
initial IRB approved grant and described in the consent forms
signed by all participants. Located in rural Anhui, China, the
cohort was composed of former plasma donors. Neuropsycholog-
ical norms were established by assessing local HIV- individuals,
matched with the HIV+, for age, education, gender and the
infection risk factor of being a former plasma donor. Neuropsy-
chological evaluations were translated into Mandarin. Chinese
psychiatric personnel were trained by our San Diego team.
Epidemiologic, treatment, clinical, and neurobehavioral data were
updated at yearly intervals [15–16]. Participant recruitment and
baseline findings have been published Heaton et al. [15]. Briefly,
at baseline 203 HIV+ and 198 HIV-participants, farmers and
laborers in the rural area of Anhui province, were enrolled into the
study at a local hospital in Fuyang City. All available HIV+
participants were re-assessed at 12 months (N=192), a 5.4% (11/
203) attrition rate. Only HIV+ participants were HLA typed. The
initial number of HLA typed individuals was 187, falling to 178 at
the 12 month assessment. Of the 178 HLA typed individuals, 96
(53%) met CDC 1993 criteria for AIDS at baseline and were on
ART. Of those 96, 47 (49%) were HIV plasma RNA undetectable
(,50 copies/ml). The most common ART regimen was D4T/
ddI/NVP (62%) and the second most common was D4T/3TC/
NVP (35%). After 12 months, 19 additional HIV+participants had
progressed to AIDS, and 60.9% of the total group was receiving
ART. Sixty-one percent of the cohort was male, with an average
of 5.5 years of education. Fifty-one percent of the 178 were HBV
surface antibody positive and 94% were HCV antibody positive
(in serum). Self reported HIV infection duration was estimated at
154 months (Standard deviation=42).
By design at 12 months post-baseline, half of the baseline HIV-
participants (N=101) were re-assessed in order to develop
normative standards for neuropsychological change. The
101 HIV-participants had been randomly selected in order to
compose a sample representative of the total baseline group with
respect to demographic and baseline neuropsychological charac-
teristics [27].
Procedure
Participants underwent comprehensive neurocognitive and
neuromedical evaluations, and a structured psychiatric exami-
nation. Examinations (baseline and follow-up) were performed
by Chinese psychiatric staff trained and certified in the
standardized testing procedures by the U.S. research team
(RKH). Details of the neuropsychology battery selection and
adaptation for use in China are provided in Cysique et al. [16],
and Heaton et al. [15]. Neurocognitive impairment status was
defined by the global deficit score (GDS), that represents a
summary score for multiple cognitive domains (Verbal Fluency,
Attention/Working Memory, Speed of Information Processing,
Learning, Delayed Recall, Executive Function, and Motor
Function) and ranges from 0–5, with values above 0.5
representing clinically significant impairment. The GDS can
be used as both a continuous and dichotomous variable [18].
Based upon the data of the 101 HIV- controls who received 12
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to control for practice effect and to classify significant change on
the neuropsychological test battery [27,28] Participants also
completed the Beck Depression Inventory-II (BDI-II [29]).
HLA Typing and Laboratory Tests
HLA typing and most laboratory tests were performed at the
China CDC in Beijing. DNA was extracted from whole blood
using Qiagene kits. Two digit low resolution DNA typing kits,
purchased from Texas Biogene, were used as directed. Accuracy of
database information (including HLA typing and laboratory tests)
was assessed by requests for repeat sending of random samples.
ApoE genotypes were detected in Dr Spector’s laboratory using
DNA extracted from dried blood spots using real-time PCR
(LightCycler, Roche) as described previously [26].
Data Analysis
Continuous variables were compared using two-tailed t-tests
(Table 1) or two-sided Wilkinson non-parametric tests (Tables 2, 3,
4, 5). Non-normally distributed variables in Table 1 (GDS, HIV
RNA) were square-root transformed or log transformed, respec-
tively and variances for the compared groups were similar (Levine
test). Chi-square (groups .30) or Fisher Exact test were used for
dichotomous variables (identified by an asterisk in tables). Our
HLA analyses were initially performed by separating individuals
into neurocognitively impaired and unimpaired groups and
calculating allele frequencies for HLA A, B, and DR loci, and
second, by selecting groups with and without specific alleles of
interest and comparing average values of clinical measures.
Because of the extensive polymorphism at the HLA locus, the
issue of multiple comparisons must be addressed, either by a two-
stage analysis or a gross correction of the p value (generally
considered to be overly conservative). Given that specific
predictions were formulated (based on a previous study) prior to
data collection, the analyses shown in the data tables represented
the second stage of the analysis, so that no additional adjustments
were necessary. We hypothesized that HLA DR*04 would be at a
higher frequency in the group with neurocognitive impairment
since it was the strongest predictor in previous studies. New
observations with (uncorrected) p values are identified as such in
the results, but not shown in tables. All p-values shown are two-
sided.
To identify individuals who experienced overall neurocognitive
change between baseline and follow-up, a statistical methodology
based on the multivariate regression change score approach was
used [30], Cysique et al (2010). The regression based change score
accounts for practice effect, regression towards the mean and
other factors that may influence normal test-retest variability in
neurologically stable people (e.g., test-retest interval, demograph-
ics, and overall baseline neurocognitive competence [30]. To
define neuropsychologic decline in the HIV+ sample, 101
demographically comparable HIV- individuals from the baseline
assessment were used as a reference sample to develop normative
regression formulas. The final regression formulas were then
applied to the HIV+ sample providing a z-score for each of 17
neuropsychologic variables, which reflects the degree and
direction of deviation form the predicted follow-up score. These
z-scores reflect how well or poorly the person performed at follow-
up, relative to normal expectation for someone with same baseline
performance and relevant demographic characteristics (e.g. age).
The z-scores were then summed to provide a summary regression
change score (sRCS). A 90% confidence interval was determined on
the sRCS to define ‘‘no change’’ on the test battery. That is, the
cut-off for the top 5% of the sRCS distribution of the HIV-
controls defined the ‘‘improved’’ range and the cut-off for the
bottom 5% defined the ‘‘decliners’’ range. This was applied to the
HIV+ sample. The percentage of HIV+ ‘‘decliners’’ and ‘‘non-
decliners’’ (as defined by the sRCS) in genetically defined groups
were then compared using Chi-square or Fisher Exact Test. The
GDS T-scores at follow-up were corrected for the HIV- sample
median practice effect [15,16].
Results
HLA DR*04 is Associated with Neurocognitive
Impairment
Our first analysis addressed whether the HLA DR alleles
previously reported to be associated with low CD4 T-cell
responses and neurocognitive impairment in the US were similarly
associated with neurocognitive impairment in Anhui China. To
avoid conclusions biased by a single analytic approach, data were
analyzed both cross-sectionally and longitudinally. At baseline (BL)
64 of178 (36%) of individuals in the HIV+ HLA typed group were
considered ‘‘impaired’’ with a global deficit score (GDS) greater
than 0.5. The frequency of HLA DR*04 (22% for the parent
dataset) was significantly higher in the impaired Anhui subjects
(31%) compared to the non-impaired group (17%, p=0.039 by
Chi Square).
To further examine the HLA DR*04 associations, those
individuals with one or more copies of HLA DR*04 (N=42 of
178) were compared with those without HLA DR*04 (N=136 of
178), and clinical measures compared. Group averages are
presented in Table 1 with p-values determined by two-tailed t-
test. Although the HLA DR*04+ and DR*042 groups were
similar in terms of ART, CD4 levels, and nadir CD4, those with
HLA DR*04+ were more impaired at both baseline and at 12
months, compared to those without HLA DR*04. HIV RNA
levels were lower in those with HLA DR*04 (both at baseline and
12 months) compared to those without. Individuals with DR*04
were also more depressed (higher BDI) at baseline but not at 12
months. Other alleles higher in the baseline impaired group, but
Table 1. Individuals with HLA DR*04 tend to be more
impaired but also have lower HIV RNA.
Measure Interval DR*04+ DR*042 p value
N 42 (22%) 136 (t-test)
GDS Baseline 0.69 0.57 0.04
GDS 12 mo 0.74 0.62 0.07
%ART Baseline 60% 52% 0.48*
CD4 Baseline 369 364 0.44
CD8 Baseline 924 882 0.3
CD4 Nadir 267 276 0.47
HRNAlog Baseline 2.98 3.39 0.08
HRNAlog 12 mo 2.86 3.36 0.04
*FET
Values (other than sample N) in tables represent averages of the indicated
variables. BL is baseline score and 012 is twelve month evaluation point. GDS is
‘global deficit score’ and neurocognitive impairment is defined as $0.5. GDS
values were square root transformed. Percent ART is percentage of group on at
least 2 anti-retroviral medications. CD4 and CD8 value are absolute cells/
microliter. HRNA log is log value of HIV RNA copies/ml with a lower limit of
detection of 50 copies. All statistical tests are two tailed, values ,.05 are
underlined and an asterisk denotes Fisher Exact Test.
doi:10.1371/journal.pone.0032303.t001
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versus 2.5%, p=0.005) and HLA B*15 (32% versus 5%,
p=0.011) by Fisher’s exact test. HLA B*15 has been identified
as a risk factor for general HIV disease progression in other studies
in China, but no mechanism has been described [3,6].
HLA DR*04 is Associated with Neurocognitive Decline in
Participants with Detectable HIV RNA
Since the cross sectional correlations between impairment and
HLA alleles reported in Table 1 could represent HIV independent
mechanisms (such as HLA DR*049s reported association with
ASD [21]), we also examined neurocognitive decline as a function
of HIV RNA levels. Comparison of neurocognitive decline during
one year of uncontrolled (compared to controlled) HIV infection
should highlight an HIV associated mechanism. Uncontrolled
HIV disease was defined as detectable HIV RNA ($50 copies/ml,
with or without ART) during the 12 month period. Forty-nine of
178 (27%) HLA typed individuals qualified as significant
neurocognitive ‘‘decliners’’ (based on the 95% summary ‘‘change
score’’ cutoff). Neurocognitive decliner and non-decliner groups
were stratified according to presence or absence of detectable
plasma HIV RNA and HLA A, B, and DR allele frequencies
calculated for all 4 groups.
The percent decline and clinical averages for 4 groups (+/
2DR*04, +/2 HIV RNA) are shown in Table 2. The only (HLA
A, B, or DR) allele associated with significant neurocognitive
decline in the HIV RNA detectable group was HLA DR*04.
Neurocognitive decline was highest (45%) for HLA DR*04
positive individuals with detectable HIV RNA, compared to or
those with HLA DR*04, HIV RNA suppressed (20% decline,
p=0.04,) or those without HLA DR*04 and HIV RNA detectable
(26% decline, p=0.06). HIV RNA levels for HLA DR*04 positive
RNA detectable group remained lower than the HLA DR*04
negative RNA detectable group, suggesting that the lower level of
HIV RNA in the HLA DR*04+ group in Table 1 was not due to a
higher frequency of RNA undetectable individuals. Neither HLA
B*13 or B*15, which were associated with baseline impairment,
were linked to neurocognitive decline. HLA B*46, which has been
identified as a risk factor for HIV seroconversion in China [2],
however, tended to be more common in the decliner group
p=0.06. HLA B*58, associated with slower HIV progression [14]
was rare in this cohort, so that the over-representation in the non
decliner group was not statistically significant (p=0.09).
Table 2. Individuals who are DR*04+ and have detectable HIV RNA have a greater risk of neurocognitive decline.
Measure Interval DR*04+ DR*042 DR*04+ DR*042 RNA+DR*04+ DR*04+RNA+ DR*04+
RNA+ RNA+ RNA2 RNA2 vs DR*042 vs RNA2 RNA+
N 2 2 8 72 04 9p = p = v s o t h e r s
NC Decline BL-012 45% 26% 20% 24% .06* .05* .04*
%ART 12 mo 38% 44% 85% 90% 0.45 0.001
CD4 Nadir 268 285 266 230 0.33 0.49
HRNAlog 12 mo 3.91 4.3 1.69 1.69 .04*
Values (other than sample N) in tables represent averages of the indicated variables. BL is baseline score and 012 is twelve-month evaluation point. ‘‘Decline’’ is
significant neurocognitive decline between BL and 012 (see methods). Percent ART is percentage of group on at least 2 anti-retroviral medications. CD4 values are
absolute cells/microliter. HRNA log is log value of HIV RNA copies/ml with a lower limit of detection of 50 copies. All statistical tests are two tailed, values ,.05 are
underlined. A p value with an asterisk denotes Fisher’s Exact Test and others were derived using Wilcoxen non-parametric test.
doi:10.1371/journal.pone.0032303.t002
Table 3. HLA Class I alleles that specifiy recognition of conserved HIV sequences protect from neurocognitive impairment and
decline.
Interval
At least one protective Class I allele:
(A*03,*33,B*27,*57,*58)
No protective
Class I allele p value FET*, Wilkinson
N4 7 1 3 1
% NC Decline BL-12 mo 15% (7) 31% (42) .024*
GDS BL 0.35 0.53 0.014
GDS 12 mo 0.4 0.61 0.008
%On ART 12 mo 60% 63% 0.77*
CD4 Nadir 249 271 0.57
HIV RNA log 12 mo 3.42 3.19 0.323
%RNA,50 12 mo 28% 36% .55*
%DR*04 21% 23% .87*
Values (other than sample N) in tables represent averages of the indicated variables. BL is baseline score and 012 is twelve month evaluation point. ‘‘Decline’’ is
significant neurocognitive decline between BL and 012 (see methods). GDS is ‘global deficit score’ and neurocognitive impairment is defined as $0.5. Percent ART is
percentage of group on at least 2 anti-retroviral medications. CD4 and CD8 value are absolute cells/microliter. HRNA log is log value of HIV RNA copies/ml with a lower
limit of detection of 50 copies. All statistical tests are two tailed, values ,.05 are underlined. A p value with an asterisk denotes Fisher’s Exact Test and others were
derived using Wilcoxen non-parametric test.
doi:10.1371/journal.pone.0032303.t003
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A second major goal of the study was to determine whether
HLA Class I alleles (HLA A,B) associated with slower HIV disease
progression in other research studies can protect from neurocog-
nitive decline. The protective alleles identified in US and Europe:
B*27, B*57, B*58 are, rare in Asia (7, 5, and 6 individuals,
respectively in our cohort of 178). However, in the interest of
identifying conserved HIV viral epitopes (and the alleles that
present them) for local vaccine design, studies in China have
systematically analyzed HLA restricted CD8 T-cell recognition.
Results validated the identification of B*27, B*57, and B*58, but
additional alleles: HLA A*03 and A*33 were also newly identified
as recognizing conserved HIV gag sequences [7,31].
As noted above, in the current study, HLA B*58 was more
common among HIV infected participants with stable neurocog-
nitive status. HLA B*27 and 57, the most protective in US studies,
were over represented in the non-decliner subset (7 of 7 for B*27),
but the frequencies of these 3 alleles were too low in China for
analysis individually. Since the question posed was whether the
presence of any (rather than one specific) HLA Class I allele (that
presented conserved HIV sequences) was associated with protec-
tion from neurocognitive impairment and decline, we performed a
collective analysis for both the newly identified (in China) and
published protective alleles, asking whether the presence of any
one or more preserved cognition (i,e, no impairment or decline)
compared to persons without. This selection identified 47 of 178
(26%) had one or more copies of: HLA A*03, A*33, B*27, B*57 or
B*58 alleles.
Neurocognitive impairment status and decline rates were
compared for those with and without the five ‘‘protective’’ Class
I alleles and results are shown in Table 3. Percent neurocognitive
decline was significantly higher in the group without a protective
HLA Class I allele (p=0.024). In addition, the mean impairment
scores (mean GDS at baseline) of individuals with protective Class
I (PCI) alleles were significantly lower (p=0.014), remaining in the
normal range (GDS,0.5) over the year of follow-up, while the
group without a PCI allele were on average, impaired (GDS $.05)
at baseline and declined more dramatically. The frequency of
ART and presence of the HLA DR*04 allele were comparable in
the PCI versus no PCI patient groups. Nadir CD4 and percent
HIV RNA undetectable tended to be lower, and level of viremia
slightly higher in the PCI group. Ten of the 47 individuals had 2 or
more PCI alleles and none showed neurocognitive decline over the
year of follow-up (data not shown).
Table 4. The low CD4 response allele, HLA DR*04, limits the efficacy of protective HLA Class I alleles.
Measure Interval PCI+ PCI+ PCI2 PCI2 PCI+DR*04-vs
DR*042 DR*04+ DR*042 DR*04+ PCI-DR*04+
N 36 11 100 31 36 vs 31
%NC Decline BL-12 mo 11% 27% 31% 35% 0.021*
GDS. Baseline 0.32 0.45 0.53 0.7 0.003
GDS 12 mo 0.35 0.58 0.61 0.75 0.003
CD4 Nadir 245 259 271 272 0.73
HIV RNA 12 mo 3.43 3.38 3.19 2.67 0.032
%on ART 12 mo 61% 64% 59% 68% 0.68*
Values (other than sample N) in tables represent averages of the indicated variables. BL is baseline score and 012 is twelve-month evaluation point. ‘‘NC Decline’’ is
significant neurocognitive decline between BL and 012 (see methods). GDS is ‘global deficit score’ and neurocognitive impairment is defined as $0.5. Percent ART is
percentage of group on at least 2 anti-retroviral medications. CD4 and CD8 value are absolute cells/microliter. HRNA log is log value of HIV RNA copies/ml with a lower
limit of detection of 50 copies. All statistical tests are two tailed, values ,.05 are underlined. A p value with an asterisk denotes Fisher’s Exact Test and others were
derived using Wilcoxen non-parametric test.
doi:10.1371/journal.pone.0032303.t004
Table 5. HLA DR*04 and ApoE4 have a synergistically negative effect on cognition.
Measure Interval E4+vs E4-DR*04-vs
E4+DR*042 E4-DR*04+ DR*04+ E4-DR*042 E4+DR*04+ E4+DR*04+
N 3 33 3p = 1 0 3 9 p =
Edu (yrs) 5.2 5.7 0.05 5.8 5.1 0.52
%ART BL 45% 39% 0.80* 55% 67% 0.73*
RNAlog 12 mo 3.74 2.86 0.07 3.22 2.85 0.45
GDS BL 0.74 0.55 0.91 0.42 0.87 0.02
GDS 12 mo 0.75 0.63 0.32 0.51 0.9 0.07
Values (other than sample N) in tables represent averages of the indicated variables. BL is baseline score and 012 is twelve month evaluation point. Edu is years of
education. GDS is ‘global deficit score’ and neurocognitive impairment is defined as $0.5. Percent ART is percentage of group on at least 2 anti-retroviral medications.
CD4 and CD8 value are absolute cells/microliter. HRNA log is log value of HIV RNA copies/ml with a lower limit of detection of 50 copies. All statistical tests are two
tailed and values ,.05 are underlined. A p value with an asterisk denotes Fisher’s Exact Test and others were derived using Wilcoxen non-parametric test.
doi:10.1371/journal.pone.0032303.t005
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Decline, But Remains Associated with Lower Plasma
Viremia
Effective HLA Class I restricted CD8+ T-cell cytotoxic activity
generally requires ongoing support from HLA Class II restricted
CD4+ T-cells [20]. This would predict that low CD4 T-cell
activation, such as that associated with HLA DR*04, could limit
effective cytotoxic activity of PCI CD8+ T-cells against HIV
infected cells. To determine if the presence of HLA DR*04
reduced the protective neurocognitive effect of the PCI alleles, the
PCI positive and negative groups were subdivided according to
presence or absence of HLA DR*04. The 4 groups are shown in
Table 4, with a statistical comparison of the 2 extremes (PCI+
DR*042 and PCI- HLA DR*04+). In addition to the lower
percent decline, the group with protective Class I alleles tended to
decline within the normal range, while the group without
protective alleles declined across the impairment cut off and
within the impaired range. Considering the mean neurocognitive
impairment scores at baseline and follow-up as well as the
frequency of neurocognitive decline, the trends suggest that
presence of HLA DR*04 reduces the protective effect of the
PC1 alleles on cognition. This effect is independent of CD4 and
CD8 counts (data not shown), as well as CD4 nadir. Consistent
with previous analyses, HLA DR*04 remained associated with
lower HIV RNA levels.
Synergistic Consequences of ApoE4 and HLA DR*04
Allele frequencies for other loci were also analyzed as part of
this study. While most of the findings regarding non-HLA loci are
published separately [26], we did investigate potential interactions
between HLA alleles and non-HLA alleles that influenced
cognition in the Anhui cohort. The most intriguing observation
related to the ApoE4 allele, which has been associated with
Alzheimer’s disease occurrence and severity [32,33]. Similar to
HLA DR*04, ApoE4 was present in 22% of the cohort and
associated with baseline neurocognitive impairment. Of note, both
alleles are individually associated with syndromes that impact
cognition (autism and Alzheimer’s). However, in contrast to HLA
DR*04 where the association with neurocognitive decline was
observed in the HIV RNA detectable group, ApoE4 was most
strongly associated with neurocognitive decline in the antiretrovi-
ral treated, HIV RNA ,50 group, suggesting different mecha-
nisms of action for the two alleles (data not shown). To determine
whether there was an additive or synergistic effect on cognition
between HLA DR*04 and ApoE4 when both were present in the
same individual, the mean neurocognitive scores of the 4
subgroups for this analysis (ApoE4 only, HLA DR*04 only,
Neither, Both) are compared in Table 5, with p values shown
below each pair. As the two gene loci are on different
chromosomes, (ApoE on 19 and HLA on 6), the two sorted
independently. Individuals with either allele alone had mean GDS
scores above the impairment cut-off (0.5), but means of individuals
with ApoE4 tended to be higher than those with HLA-DR*04.
Comparison of degree of impairment of those with both HLA
DR*04 and ApoE4 and those with neither allele, revealed
significantly greater impairment in the group with both alleles,
for both average impairment score at BL and 12 months and
percent of those impaired. Specifically, there was a 78%
impairment rate among the 9 subjects with both compared to a
34% impairment rate among the other 169 subjects. The
interaction was synergistic since there is a statistically significant
association between having ‘‘both ApoE4 and HLA-DR4’’ vs.
‘‘either one alone or neither’’ (p=0.01, two-sided Fisher’s Exact
test). ART, CD4 nadirs and levels and CD8 levels were similar for
all groups (not shown). Consistent with other group comparisons,
plasma HIV RNA levels were lower for individuals with HLA
DR*04.
Discussion
HAND is a chronic aspect of HIV disease that appears to be
initiated by HIV and facilitated by immunosuppression. In that
sense, protection from neuropsychological impairment would be
predicted to correlate with immune and genetic markers (such as
HLA*B27, B57, and B58) that are associated with long-term
control of HIV viremia and low rate of CD4 depletion. Since not
all HIV infected individuals develop HAND (typical estimates are
around 40%), genetic associations could identify those at greatest
risk for HAND for preventive treatment, as well as contributing to
our understanding of pathogenic mechanisms. The findings
presented here confirm and extend previous observations [4] that
HLA alleles coding for a low CD4 T-cell response (specifically
HLA DR*04) are associated with HAND and neuropsychological
decline. Decline was measured as change over one year, a
relatively short period in the course of HIV disease. However, a
higher rate of neuropsychological decline was detected in
participants with detectable HIV RNA who had the DR*04 allele
(45%), compared to those without the DR*04 allele (25%), those
with DR*04 who had detectable HIV viremia (20%), or those
without DR*04 and plasma HIV RNA suppressed (24%).
These findings also suggest that despite a relatively short interval
(1 year), clinically meaningful changes can be detected and linked
to host genetic factors.
The association of HLA DR*04 with low immune responses has
been observed in other contexts. It has been shown that T-cells
from autistic (HIV-) individuals with HLA DR*04+ proliferate
poorly to mitogens [21]. The major protective role played by CD4
T-cells in HIV disease is thought to be their helper function for
CD8 T-cells. Without sustained CD4 help, CD8 T-cell cytotoxic
activity is transient, even in the presence of chronic viremia [20].
This suggests that poor CD4 support could lead to failure of CD8
cytotoxic activity towards HIV infected cells, even for those
individuals with HLA Class I alleles coding for recognition of
conserved regions of the virus. Low CD4 activity also generally
leads to lower antibody responses.
Although HLA DR*04 was associated with HIV related
neurocognitive impairment, it was also significantly related to
lower plasma HIV RNA levels (compared to those without
DR*04). This is counterintuitive since most symptoms of HIV
infection as well as neurocognitive decline overall correlate
positively with plasma viremia. However, the association between
HLA DR*04 and low plasma viremia was detected previously (in
conjunction with low T-cell proliferative responses to HIV), and
appears consistently in the data shown in this report. Since HIV
replicates best in activated CD4 T-cells, the most straightforward
explanation for the HLA DR*04 association with lower plasma
HIV RNA levels is that less T-cell activation and proliferation
leads to less HIV replication.
Identifying and combining genetic and clinical risk factors
improves our understanding of HIV pathogenesis, provides
epidemiologic information and has implications for treatment
and prevention of neuropsychological impairment. For instance,
from the genetic and virologic data acquired, the group with the
lowest rate of neuropsychological decline (8%, which means
virtually no decline given the use of the 90% confidence interval)
would be: HLA DR*04 negative, at least one protective Class I
HLA & HIV-Associated Cognitive Impairment in China
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e32303allele, and HIV RNA undetectable. In contrast, the group with the
highest rate of neurocognitive decline (45%) were HLA DR*04+
and detectable HIV RNA (a stronger influence in the DR*04
group than the presence or absence of a protective Class I allele).
The co-detection of contradictory markers underscores the
difficulty of predicting neurocognitive decline and risk of HAND
for any individual. A case in point is one Anhui participant who is
homozygous for HLA DR*04, is ApoE4+, but also has 3 protective
Class I alleles (B*27, A*03, A*33) and has plasma HIV RNA
,2500 copies/ml, but has never been on ART. Her CD4 levels
remain .500/mm
3, but she was neuropsychologically impaired at
baseline. At 12 months she tested neuropsychologically normal,
without any CNS targeted treatment (her only medication was
Penicillin) and was plasma HIV RNA undetectable.
The observation that no single gene unequivocally guarantees
HAND suggests the interaction of multiple host genes and
environmental factors come into play and influence neurocogntive
status in the context of HIV infection. Although the significance
levels for associations between HLA DR*04, neurocognitive
impairment/decline and low levels of viremia were modest (p
values around 0.04), the pattern was consistent throughout the
analyses, regardless of the comparison groups. Given the diversity
at the HLA locus, it is impressive that any single gene can be
shown to have a significant impact on neurocognitive impairment
or HIV RNA levels. The consistency of the DR*04 associations
(high risk of HAND, lower HIV RNA) in the Anhui and US
cohort are especially striking given differences between the cohorts
with respect to some HLA alleles (DR*03, DR*09, B*48), gender
percentages (40% female in Anhui versus 8% in US), HCV
infection (90% in Anhui versus 30% in US), level of education (an
average of 5 years in Anhui versus 12 in the US).
Mechanisms of many HLA associations have yet to be defined
and much remains to be elucidated concerning interactions
between alleles. Since individuals with HLA-DR*04 have dem-
onstrated low CD4 responses to CMV, HSV, and the mitogen
PHA in our previous studies, the low CD4 response appears to be
non (antigen) specific, a result of low levels of DR*04 protein
expression or poor interaction of DR*04 with peptides or signaling
molecules [4]. Although there are always concerns that apparent
HLA associations with any one allele are actually an association
with a closely linked gene, the observation that the HLA Class I
protective alleles and DR*04 sorted independently in our analyses
(despite proximity on Chromosome 6), supports allele identifica-
tion.
The extensive diversity at the HLA B locus (32 possible alleles
for Anhui) makes single allele analysis difficult. In an attempt to
simplify, a number of studies have examined HLA B locus data
according to the expression of shared public specificities (Bw
expression). This classification resolves the B alleles into B*w4,
B*w6 and B*15. B*w4 is reportedly protective (regarding HIV
disease progression) in US cohorts, but not in China [3,6,34]. We
compared frequencies B*w4 and B*w6 in groups with neurocog-
nitive impairment and decline in the Anhui cohort, but consistent
with other China studies, no protective associations for B*w4 or
detrimental effects of B*w6 were detected. HLA B*13 (has B*w4)
was actually over-represented in the Anhui baseline impaired
group, but this finding was not predicted and would not be
significant with corrections. HLA B*15 was over-represented in
the baseline impaired group and has been identified as a marker of
disease progression in other Chinese HIV cohorts [3]. As noted in
the results, a higher frequency of HLA B*46 was detected in the
Anhui neuropsychological decliners. This allele is rare in non-
Asians and was not part of our initial hypothesis, but other studies
in China have reported associations with both HIV seroconversion
and disease progression [2,3]. The consistency of these HLA B
associations will be assessed in future study populations.
Diversity among HIV strains and relative neurotropic character
are important variables that were not addressed in this report.
Preliminary results suggest that the Anhui plasma donor cohort is
primarily infected with HIV-1 subtype B, with a few individuals
positive for C.
It is possible that some of our correlates with baseline
neurocognitive impairment are independent of HIV, reflecting
mild autism spectrum disorder (DR*04) [22] or very early
symptoms of Alzheimer’s disease (ApoE4) [32]. The association
of HLA DR*04 with neurocognitive decline over a year with
detectable HIV RNA, however suggests an HIV associated
mechanism for that allele. On the other hand, consistent with
other reports, the ApoE4 association with neurocognitive impair-
ment in this study was not clearly linked to HIV disease (although
ApoE4 has been associated with more rapid HIV disease
progression) [35]. At present, there is insufficient longitudinal
data to assess the effects of either ApoE4, HLA DR*04, or A*03,
A*33, B*27, B*57, or B*58 on HIV disease progression in this
cohort. The small number of HIV infected individuals with both
HLA DR*04 and ApoE4 and lack of an HIV negative control
group for HLA associations precludes further analysis. Our
working hypothesis concerning the combinatorial effect on
cognition is that the presence of the two alleles (ApoE4 and
HLA-DR*04) in the same host predisposes to low levels of
academic achievement (before HIV infection) leading to little
cognitive ‘‘reserve’’ following HIV infection. Regardless of the role
of HIV, it is certainly of interest that the co-localization of these
two alleles in one host can have a profoundly negative impact on
cognition.
Overall, the data presented support the initial hypothesis that
HLA DR*04 has a negative impact on neurocognitive status and
promotes neurocognitive decline in the context of active HIV
disease, but is also associated with lower HIV plasma viremia,
consistent with the idea of minimal CD4 T-cell activation. HLA
Class I alleles that present conserved viral sequences are
protective, but, as predicted by models of CD4/CD8 T-cell
interdependence, the HLA Class I protective effect is minimized
by the presence of HLA DR*04. In vitro modeling of T-cell
activation as well as epidemiologic studies will be needed to
confirm mechanisms.
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